Evidence map›Paper›PMID 26643507›Full record

SynthesisChinese journal of integrative medicine2016

A systematic review of anticancer effects of radix astragali.

Yeehong Jung, Uimin Jerng, Sookyung Lee

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Chinese journal of integrative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Protective effect ofBiomedical reports · 2025
    Article
  4. Article
  5. Article
  6. Research Progress on the Treatment of Related Diseases WithDrug design, development and therapy · 2025
    Review
  7. Article
  8. Research Progress on the Anticancer Activity of Plant Polysaccharides.Recent patents on anti-cancer drug discovery · 2024
    Review
  9. Review
  10. Article
  11. Molecular mechanisms of astragaloside‑IV in cancer therapy (Review).International journal of molecular medicine · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. RSC advances · 2019
    Article
  17. Article
  18. Article
  19. Frontiers in pharmacology · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Yeehong JungDepartment of Clinical Oncology, College of Korean Medicine, Kyung Hee University Hospital at Gangdong, 892 Dongnamro, Gangdong-gu, Seoul, 05287, Republic of Korea.
Uimin JerngClinical Research Division, Korea Institute of Oriental Medicine, 1672, Yuseong-daero, Yuseong-gu, Daejeon, 34054, Republic of Korea.
Sookyung LeeDepartment of Clinical Oncology, College of Korean Medicine, Kyung Hee University Hospital at Gangdong, 892 Dongnamro, Gangdong-gu, Seoul, 05287, Republic of Korea. sookyung@khu.ac.kr.
Kyung Hee University Hospital at Gangdong · KRKorea Institute of Oriental Medicine · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo review the anticancer effects of Radix astragali (RA), one of the most commonly used herbs to manage cancer in East Asia, and its constituents and to provide evidence of clinical usage through previously performed clinical studies.

methodsPreclinical and clinical studies related to the anticancer effects of RA were searched from inception to November 2013 in electronic databases. Two reviewers independently investigated 92 eligible studies, extracted all the data of studies and appraised methodological quality of clinical trials. The studies were categorized into in vitro and in vivo experimental studies and clinical studies, and analyzed by saponins, polysaccharides, and flavonoids of RA constituents, RA fraction, and whole extract.

resultsIn preclinical studies, RA was reported to have tumor growth inhibitory effects, immunomodulatory effects, and attenuating adverse effects by cytotoxic agents as well as chemopreventive effects. Saponins seemed to be the main constituents, which directly contributed to suppression of tumor growth through the activation of both intrinsic and extrinsic apoptotic pathway, modulation of intracellular signaling pathway, and inhibition of invasion and angiogenesis. Flavonoids suppressed tumor growth through the similar mechanisms with saponins. Polysaccharides showed immunomodulatory effects, contributing tumor shrinkages in animal models, despite the low cytotoxicity to cancer cells. Most of the clinical studies were performed with low evidence level of study designs because of various limitations. RA whole extracts and polysaccharides of RA were reported to improve the quality of life and ameliorate myelosuppression and other adverse events induced by cytotoxic therapies.

conclusionThe polysaccharides, saponins, and flavonoids of RA, and the whole extract of RA have been widely reported with their anticancer effects in preclinical studies and showed a potential application as a adjunctive cancer therapeutics with the activities of immunomodulation, anti-proliferation and attenuation of adverse effects induced by cytotoxic therapy.

Indexed as

AnimalsAntineoplastic AgentsAstragalus propinquusClinical Trials as TopicDrugs, Chinese HerbalHumansAntineoplastic AgentsDrugs, Chinese HerbalHuang Qianticancer agentscancerRadix astragalisystematic review

Identifiers

PMID26643507
OpenAlexW2289497158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.